Neurophet

뉴로핏 · 380550

Information Technology Software · KOSDAQ

Small-cap

Market cap US$117M (₩161.5B)

Overview

Neurophet develops AI-powered software that helps doctors read brain scans, MRI and PET images, to detect and monitor Alzheimer's disease and other neurodegenerative conditions.

Its core products, AQUA and SCALE PET, analyze brain-region volumes and amyloid-protein accumulation to support diagnosis, treatment decisions, and side-effect monitoring. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company supplies its solutions to diagnostic centers, secondary and tertiary hospitals, and global pharmaceutical firms running clinical trials.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$1.9M
Operating profit · FY2025
−US$12M
Net income · FY2025
−US$16.2M

Revenue

  • FY2025US$1.9M

Operating profit

  • FY2025−US$12M

Net income

  • FY2025−US$16.2M

Key ratios (FY2025)

ROE
-115.1%
Debt/Eq
38.2%
Op. margin
-632.8%
Net margin
-856.1%
Rev. YoY
N/A (see filing)

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.